Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study
dc.contributor.author | Wesolowska-Andersen, A | |
dc.contributor.author | Brorsson, CA | |
dc.contributor.author | Bizzotto, R | |
dc.contributor.author | Mari, A | |
dc.contributor.author | Tura, A | |
dc.contributor.author | Koivula, R | |
dc.contributor.author | Mahajan, A | |
dc.contributor.author | Vinuela, A | |
dc.contributor.author | Tajes, JF | |
dc.contributor.author | Sharma, S | |
dc.contributor.author | Haid, M | |
dc.contributor.author | Prehn, C | |
dc.contributor.author | Artati, A | |
dc.contributor.author | Hong, M-G | |
dc.contributor.author | Musholt, PB | |
dc.contributor.author | Kurbasic, A | |
dc.contributor.author | De Masi, F | |
dc.contributor.author | Tsirigos, K | |
dc.contributor.author | Pedersen, HK | |
dc.contributor.author | Gudmundsdottir, V | |
dc.contributor.author | Thomas, CE | |
dc.contributor.author | Banasik, K | |
dc.contributor.author | Jennison, C | |
dc.contributor.author | Jones, A | |
dc.contributor.author | Kennedy, G | |
dc.contributor.author | Bell, J | |
dc.contributor.author | Thomas, L | |
dc.contributor.author | Frost, G | |
dc.contributor.author | Thomsen, H | |
dc.contributor.author | Allin, K | |
dc.contributor.author | Hansen, TH | |
dc.contributor.author | Vestergaard, H | |
dc.contributor.author | Hansen, T | |
dc.contributor.author | Rutters, F | |
dc.contributor.author | Elders, P | |
dc.contributor.author | t'Hart, L | |
dc.contributor.author | Bonnefond, A | |
dc.contributor.author | Canouil, M | |
dc.contributor.author | Brage, S | |
dc.contributor.author | Kokkola, T | |
dc.contributor.author | Heggie, A | |
dc.contributor.author | McEvoy, D | |
dc.contributor.author | Hattersley, A | |
dc.contributor.author | McDonald, T | |
dc.contributor.author | Teare, H | |
dc.contributor.author | Ridderstrale, M | |
dc.contributor.author | Walker, M | |
dc.contributor.author | Forgie, I | |
dc.contributor.author | Giordano, GN | |
dc.contributor.author | Froguel, P | |
dc.contributor.author | Pavo, I | |
dc.contributor.author | Ruetten, H | |
dc.contributor.author | Pedersen, O | |
dc.contributor.author | Dermitzakis, E | |
dc.contributor.author | Franks, PW | |
dc.contributor.author | Schwenk, JM | |
dc.contributor.author | Adamski, J | |
dc.contributor.author | Pearson, E | |
dc.contributor.author | McCarthy, MI | |
dc.contributor.author | Brunak, S | |
dc.date.accessioned | 2023-02-24T15:05:02Z | |
dc.date.issued | 2022-01-04 | |
dc.date.updated | 2023-02-24T14:39:23Z | |
dc.description.abstract | The presentation and underlying pathophysiology of type 2 diabetes (T2D) is complex and heterogeneous. Recent studies attempted to stratify T2D into distinct subgroups using data-driven approaches, but their clinical utility may be limited if categorical representations of complex phenotypes are suboptimal. We apply a soft-clustering (archetype) method to characterize newly diagnosed T2D based on 32 clinical variables. We assign quantitative clustering scores for individuals and investigate the associations with glycemic deterioration, genetic risk scores, circulating omics biomarkers, and phenotypic stability over 36 months. Four archetype profiles represent dysfunction patterns across combinations of T2D etiological processes and correlate with multiple circulating biomarkers. One archetype associated with obesity, insulin resistance, dyslipidemia, and impaired β cell glucose sensitivity corresponds with the fastest disease progression and highest demand for anti-diabetic treatment. We demonstrate that clinical heterogeneity in T2D can be mapped to heterogeneity in individual etiological processes, providing a potential route to personalized treatments. | en_GB |
dc.description.sponsorship | Medicines Initiative Joint Undertaking | en_GB |
dc.description.sponsorship | Novo Nordisk Foundation | en_GB |
dc.description.sponsorship | Wellcome Trust | en_GB |
dc.identifier.citation | Vol. 3, article 100477 | en_GB |
dc.identifier.doi | https://doi.org/10.1016/j.xcrm.2021.100477 | |
dc.identifier.grantnumber | 115317 | en_GB |
dc.identifier.grantnumber | NNF17OC0027594 | en_GB |
dc.identifier.grantnumber | NNF14CC0001 | en_GB |
dc.identifier.grantnumber | 102820/Z/13/Z | en_GB |
dc.identifier.grantnumber | 090532 | en_GB |
dc.identifier.grantnumber | 098381 | en_GB |
dc.identifier.grantnumber | 106130 | en_GB |
dc.identifier.grantnumber | 203141 | en_GB |
dc.identifier.grantnumber | 212259 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/132542 | |
dc.identifier | ORCID: 0000-0002-0883-7599 (Jones, Angus) | |
dc.identifier | ORCID: 0000-0001-5620-473X (Hattersley, Andrew) | |
dc.identifier | ORCID: 0000-0003-3559-6660 (McDonald, Timothy) | |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier | en_GB |
dc.relation.source | Data and code availability: Data: Requests for access to IMI DIRECT data, including data presented here, can be made to the Lead Contact. All data areavailable without restriction in a secure environment. Code: Our manuscript does not report any novel custom code. The software for the main clustering method is available as an R package and was published in reference 10 and 11. Any additional information required to reanalyze the data reported in this paper is available from the Lead Contact upon request. | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/35106505 | en_GB |
dc.rights | © 2021 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | en_GB |
dc.title | Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2023-02-24T15:05:02Z | |
dc.identifier.issn | 2666-3791 | |
exeter.article-number | 100477 | |
exeter.place-of-publication | United States | |
dc.description | This is the final version. Available from Elsevier via the DOI in this record. | en_GB |
dc.identifier.journal | Cell Reports Medicine | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2021-11-23 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2022-01-04 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2023-02-24T14:57:43Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2023-02-24T15:05:06Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2022-01-04 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2021 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).